PolyMedics Innovations (PMI) is a R&D-driven specialist in innovative biomaterials for the effective treatment of wounds. PMI is an owner-managed German Mittelstand Company headquartered in Denkendorf, Germany with a subsidiary in Atlanta, USA. Distribution covers over 30 markets globally. PMI’s state-of-the-art manufacturing plant is located in Germany.

PolyMedics Innovations was founded in 2003 to develop, produce and market innovative biomaterials and systems for the treatment of wounds.

PolyMedics Goal & Mission

Our goal is to improve woundcare for patients, physicians and societies through innovation and collaboration. The latest scientific insights in the field of wound care form the basis for PolyMedics Innovations. Our continuous research and constant new discoveries resulted in unique materials and treatment concepts.

Our Mission: Improving wound care for patients, physicians and societies through innovation and collaboration.

Here are our 4 key values that drive our actions:


PMI Values (1)

Featured Products


The SUPRATHEL® artificial wound and burn dressing is a thin elastic membrane, adapts itself optimally to the surface of the wound, and adheres on its own. SUPRATHEL® is only applied once onto the previously cleaned and disinfected wound where it remains until the wound is completely healed. After it is applied, the membrane becomes translucent and makes the inspection of the healing process possible. SUPRATHEL® can be removed easily from the healed skin parts without causing any pain.

SUPRATHEL® was developed for the management of epidermal and dermal wounds. SUPRATHEL® covers a wide range of wound care application:


SUPRA SDRM® is a novel synthetic, guided wound closure matrix, built as a bimodal foam membrane structure for the management of chronic wounds. It combines the benefits of the microporous structure known from Suprathel® that builds a protective barrier allowing the wound to heal and additional large pores which were created to enable ingrowth of blood vessels.

SUPRA SDRM® is fully synthetic – no animal derived components – polylactic acid as the main component reduces the biologic risk.

No preparation of SUPRA SDRM® matrix is necessary. When applied to the wound SUPRA SDRM® adheres well to the wound bed without the need for direct fixation. SUPRA SDRM® becomes translucent after the application allowing healthcare professionals to easily assess the wound healing.

It is available in multiple sizes and can be trimmed to meet the patient’s needs.

SUPRA SDRM® is indicated for use in the management of: